Oral Semaglutide Effective for Weight Loss in Overweight or Obesity
THURSDAY, Sept. 25, 2025 -- Oral semaglutide (25 mg) is effective for weight loss in adults with overweight or obesity without diabetes, according to a study published online Sept. 17 in the New England Journal of Medicine.
Sean Wharton, M.D., from the University of Toronto, and colleagues conducted a 71-week randomized trial at 22 sites in four countries enrolling adults without diabetes with a body mass index (BMI) of 30 kg/m2 or higher or a BMI of 27 kg/m2 or higher with at least one obesity-related complication. Participants were randomly assigned to receive oral semaglutide (25 mg) or placebo once daily plus lifestyle interventions (205 and 102 participants, respectively).
The researchers found that the estimated mean change in body weight from baseline to week 64 was −13.6 and −2.2 percent in the oral semaglutide and placebo groups, respectively. Compared with those in the placebo group, participants in the oral semaglutide group were significantly more likely to have body weight reductions of ≥5, ≥10, ≥15, and ≥20 percent and to have improved Impact of Weight on Quality of Life-Lite Clinical Trials Version Physical Function scores. Gastrointestinal adverse events occurred more often with oral semaglutide than placebo (74.0 versus 42.2 percent).
"We all knew this was coming and we all feel that it could potentially be a game changer in terms of adopting these GLP-1s across the board," Armando Castro-Tié, M.D., senior vice president and physician executive of Northwell Health's Eastern Region, said in a statement.
Several authors disclosed ties to the biopharmaceutical industry, including Novo Nordisk, which manufactures semaglutide and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Clinical Practice Guidelines Issued for Diabetes Distress
THURSDAY, Sept. 25, 2025 -- The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the...
Oral Orforglipron Yields Greater Weight Reductions Than Placebo
THURSDAY, Sept. 25, 2025 -- For adults with obesity who do not have diabetes, the oral glucagon-like peptide-1 receptor agonist orforglipron yields significantly greater...
GLP-1 Receptor Agonists Improve Glycemic, Weight Outcomes in Children With T2D
TUESDAY, Sept. 23, 2025 -- In children and adolescents with type 2 diabetes (T2D) or obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycemic, weight, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.